Health Economics›Cholangiocarcinoma›Metastatic first-line therapy

Metastatic first-line therapy

Cholangiocarcinoma · 19 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cisplatin and Gemcitabine (GC) and Durvalumab Variant #01	—	R 266 494	28d	—	~12.9 mo	—	—	2
Gemcitabine and nab-Paclitaxel Variant #02	—	R 184 204	56d	—	~11.6 mo	—	—	8
Cisplatin and Gemcitabine (GC) and Pembrolizumab Variant #01	—	R 85 180	21d	—	~12.7 mo	—	—	1
Erlotinib and Bevacizumab Variant #01	—	R 52 071	28d	~16.4 mo	~49.1 mo	~18	~R 937 282 PFS proxy · indirect	7
GEMOX-B Variant #01	—	R 42 835	28d	—	—	—	—	—
Cisplatin and Gemcitabine (GC) and nab-Paclitaxel Variant #01	—	R 32 997	21d	~11.8 mo	—	~18	~R 593 952 PFS proxy · indirect	—
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	—	~11.1 mo	—	—	8
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	~4.7 mo	~6.8 mo	~3	~R 42 639 PFS proxy · indirect	31
Gemcitabine and Mitomycin Variant #01	—	R 7 409	28d	—	—	—	—	—
ECF Variant #04	—	R 3 931	21d	—	~9.4 mo	—	—	4
FULV and Gemcitabine Variant #02	—	R 3 219	21d	—	—	—	—	—
Gemcitabine and S-1 Variant #01 Partial	—	R 2 843	21d	—	~26.1 mo	—	—	2
Capecitabine and Mitomycin Variant #01	—	R 2 711	28d	—	—	—	—	—
CapeOx Variant #01	—	R 2 384	21d	~6.7 mo	~12.2 mo	~10	~R 23 842 PFS proxy · indirect	20
GemOx Variant #01	—	R 2 335	14d	~5.0 mo	~9.0 mo	~11	~R 25 688 PFS proxy · indirect	5
Capecitabine monotherapy Variant #17	—	R 2 219	21d	~5.7 mo	~7.5 mo	~9	~R 19 974 PFS proxy · indirect	11
FELV Variant #01	—	R 1 934	21d	—	~12.0 mo	—	—	—
Gemcitabine, Cisplatin, S-1 Variant #01 Partial	—	R 1 546	14d	—	~13.5 mo	—	—	1
FULV Variant #01	—	R 1 466	35d	~5.6 mo	~13.1 mo	~5	~R 7 330 PFS proxy · indirect	15

19 of 19 regimens shown